Skip to main content
Journal cover image

Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.

Publication ,  Journal Article
Dalton, JC; Crowell, K-A; Ntowe, KW; van den Bruele, AB; DiNome, ML; Rosenberger, LH; Thomas, SM; Wang, T; Hwang, ES; Plichta, JK
Published in: Ann Surg Oncol
October 2024

BACKGROUND: The utility of sentinel lymph node biopsy (SLNB) in older patients remains controversial. Advancements in human epidermal growth factor receptor 2 (HER2)-directed therapy have revolutionized disease response rates and prognosis, supporting efforts to re-evaluate the utility of SLNB. We aimed to assess the differences in treatment and overall survival (OS) in older patients with HER2-positive breast cancer based on SLNB. METHODS: Using the National Cancer Database (2010-2020), patients ≥ 70 years of age diagnosed with cT1-2/cN0/M0, HER2-positive breast cancer were identified. Logistic regression assessed associations with SLNB, systemic therapy, and radiation. Cox proportional hazard models were used to identify factors associated with OS. Analyses were stratified by treatment sequence, i.e. upfront surgery or neoadjuvant therapy (NAT) followed by surgery. RESULTS: Of the 17,609 patients included, 94% underwent upfront surgery (n = 16,492) and the remaining underwent NAT (n = 1117). Those who underwent SLNB were more likely to receive adjuvant therapy, irrespective of nodal status {upfront surgery/systemic therapy (odds ratio [OR] 2.82, 95% confidence interval [CI] 2.17-3.67); upfront surgery/radiation (OR 3.97, 95% CI 3.03-5.21); NAT/radiation (OR 5.69, 95% CI 1.83-17.69)}. The breast pathologic complete response (pCR) rate was highest among the hormone receptor (HR)-negative/HER2-positive subtype (50.0%), of which none were found to be ypN+. Comorbidity burden was associated with significantly lower rates of adjuvant systemic therapy and worse OS. CONCLUSIONS: Patients who underwent SLNB, regardless of pN status, were more likely to receive adjuvant therapy. Nodal positivity is exceedingly rare for patients with a breast pCR following NAT, especially among the HR-negative/HER2-positive subtype. It is reasonable to consider omission of SLNB in select subgroups of older patients with HER2-positive breast cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

October 2024

Volume

31

Issue

11

Start / End Page

7621 / 7633

Location

United States

Related Subject Headings

  • Survival Rate
  • Sentinel Lymph Node Biopsy
  • Retrospective Studies
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Mastectomy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dalton, J. C., Crowell, K.-A., Ntowe, K. W., van den Bruele, A. B., DiNome, M. L., Rosenberger, L. H., … Plichta, J. K. (2024). Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer. Ann Surg Oncol, 31(11), 7621–7633. https://doi.org/10.1245/s10434-024-15812-w
Dalton, Juliet C., Kerri-Anne Crowell, Koumani W. Ntowe, Astrid Botty van den Bruele, Maggie L. DiNome, Laura H. Rosenberger, Samantha M. Thomas, Ton Wang, E Shelley Hwang, and Jennifer K. Plichta. “Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.Ann Surg Oncol 31, no. 11 (October 2024): 7621–33. https://doi.org/10.1245/s10434-024-15812-w.
Dalton JC, Crowell K-A, Ntowe KW, van den Bruele AB, DiNome ML, Rosenberger LH, et al. Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer. Ann Surg Oncol. 2024 Oct;31(11):7621–33.
Dalton, Juliet C., et al. “Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.Ann Surg Oncol, vol. 31, no. 11, Oct. 2024, pp. 7621–33. Pubmed, doi:10.1245/s10434-024-15812-w.
Dalton JC, Crowell K-A, Ntowe KW, van den Bruele AB, DiNome ML, Rosenberger LH, Thomas SM, Wang T, Hwang ES, Plichta JK. Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer. Ann Surg Oncol. 2024 Oct;31(11):7621–7633.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

October 2024

Volume

31

Issue

11

Start / End Page

7621 / 7633

Location

United States

Related Subject Headings

  • Survival Rate
  • Sentinel Lymph Node Biopsy
  • Retrospective Studies
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Mastectomy